# HSE Drugs Group

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/hse-drugs-group
Canonical HTML page: https://gethealthbrief.com/entity/hse-drugs-group

## Timeline

- **2026-08**: HSE Drugs Group recommends against reimbursement — The HSE Drugs Group cites limitations and uncertainties in evidence and price concerns in its non-recommendation for Skyclarys.
- **2026-08**: Sinn Féin leader urges Taoiseach to intervene — Mary Lou McDonald writes to Micheál Martin seeking full transparency and an urgent meeting with patients ahead of the final HSE decision.
- **2024-02**: EU approves Skyclarys — Skyclarys receives European Union marketing authorization for Friedreich's ataxia.

## Recent coverage (1 stories)

### Ireland PM Urged to Intervene as 200 Rare Disease Patients Await Drug
2026-08-16 14:35:44 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

A political row has erupted in Ireland after the HSE Drugs Group advised against reimbursing Skyclarys for Friedreich's ataxia, leaving about 200 patients in limbo. Sinn Féin leader Mary Lou McDonald is demanding full transparency and Taoiseach intervention ahead of a final HSE decision later in August.
Full story: https://gethealthbrief.com/story/ireland-pm-skyclarys-funding-transparency-200-patients

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.